Navigation Links
USPTO Grants Butamax a Further KARI Enzyme Patent

WILMINGTON, Del., July 17, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the biobutanol technology leader, today announced the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,222,017 which protects a subset of key enzymes in the isobutanol production pathway.  

(Logo: )

"We are pleased with the progress of our patent applications at the USPTO and this particular patent shows the expansion of our portfolio not just covering the fundamental pathway, but also protecting key pathway enzymes, far in advance of others in the field," commented Paul Beckwith, Butamax CEO, "This patent, and others like it soon to grant, demonstrates Butamax's strong innovation capability."

This latest patent issued from a series of applications covering a full-range of modified KARI enzymes. In this case, the enzyme subset is based on KARI enzymes having a modification that provides production efficiencies through the fundamental isobutanol biosynthetic pathway invented by Butamax. 

Butamax inventions include recombinant microorganisms that convert various feedstocks to biobutanol, process engineering for recovering biobutanol produced during fermentation, engineering design for optimized energy integrations, and various renewable fuel and chemical compositions. The depth and breadth of the portfolio reflects the synergy between Butamax's investors, BP and DuPont, as world class scientists and leaders in the biofuels industry. 

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact: Pam Schools  


SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
2. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
3. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
4. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
7. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
8. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
9. Butamax™ Responds to Gevo Patent Infringement Lawsuit
10. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
11. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is ... 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... wide range of applications such as, but not limited to, biotechnology, biomedical, drug ...
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
Breaking Biology News(10 mins):